ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.55% | -32.59% | 7.89% | 39.72% | 132.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.01% | -44.01% | -15.95% | 4.25% | 71.06% |
| Operating Income | 46.01% | 44.01% | 15.95% | -4.25% | -71.06% |
| Income Before Tax | 77.92% | 77.59% | -574.65% | -624.75% | -769.44% |
| Income Tax Expenses | 93.89% | 93.89% | -369.19% | -1,169.08% | -- |
| Earnings from Continuing Operations | 76.20% | 75.86% | -601.11% | -596.03% | -685.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.20% | 75.86% | -601.11% | -596.03% | -685.30% |
| EBIT | 46.01% | 44.01% | 15.95% | -4.25% | -71.06% |
| EBITDA | 46.03% | 44.03% | 15.96% | -4.25% | -71.13% |
| EPS Basic | 96.24% | 95.17% | -392.17% | -581.30% | -559.49% |
| Normalized Basic EPS | 94.07% | 86.20% | 44.60% | -130.01% | -124.00% |
| EPS Diluted | 96.24% | 95.17% | -392.17% | -581.30% | -559.49% |
| Normalized Diluted EPS | 94.07% | 86.20% | 44.60% | -130.01% | -124.00% |
| Average Basic Shares Outstanding | -97.09% | -98.06% | -98.91% | -99.57% | 848.73% |
| Average Diluted Shares Outstanding | -97.09% | -98.06% | -98.91% | -99.57% | 848.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
